Provectus Biopharmaceuticals, Inc. will present clinical data on PV-10 at the European Society for Medical Oncology's 2014 Congress (ESMO) in Madrid, Spain. The presentation, titled "Subgroup efficacy in patients receiving intralesional rose bengal to all existing melanoma in phase II study PV-10-MM-02," will be held on Sunday, September 28, 2014, beginning at 12:45 pm local time. Dr. Craig Dees, PhD, CEO of Provectus, said, "Provectus is happy to see our PV-10 data on melanoma shared with those attending the ESMO Congress this year." PV-10, a 10% solution of Rose Bengal that is currently being examined as a novel cancer therapeutic, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects.